What Potarlon Treats: Main Uses and Benefits

Potarlon is a medication that provides supportive relief by addressing pain and inflammation, and supports the patient during difficult episodes of discomfort. This class of product is considered relevant for the symptomatic relief of mild to moderate painful conditions and may contribute to easing the overall symptom load.

It is commonly used to help with symptoms related to physical discomfort, such as headaches, muscle pain, and dental pain, and it is applied in addressing symptoms related to inflammatory or irritative states like localized swelling and soreness. Potarlon may also be part of symptomatic management for conditions involving episodic or fluctuating manifestations, notably menstrual cramps.

By focusing on easing these symptoms, Potarlon contributes to improved comfort during periods of heightened symptoms and contributes to easing the overall symptom load during symptomatic phases.

---

Quick Fact: Relief for Pain and Inflammation Potarlon is relevant when supportive symptom management is appropriate for conditions where symptoms may intensify temporarily, and is commonly used when short-term symptomatic assistance is needed.

Potarlon (Mefenamic Acid) eligibility is strictly defined by regulatory documents, which establish specific conditions for use and absolute prohibitions. The official labeling mandates that several population groups must not use this medicine.

Eligibility Status	Population/Condition
Contraindicated	Patients with known hypersensitivity to Mefenamic Acid, aspirin, or other NSAIDs, active gastrointestinal ulceration, or chronic inflammation. It is also prohibited for use in patients with severe heart, hepatic, or renal failure, and for treating pain after Coronary Artery Bypass Graft (CABG) surgery.
Age Eligibility	Approved for use in adults and adolescents mathbf14 years of age and older. Safety and efficacy have not been established for children younger than 14 years. Older adults may use it, but require caution due to a higher documented risk of adverse renal and GI events.
Pregnancy/Lactation	Use is contraindicated at or after 30 weeks gestation due to potential fetal risk, and not recommended at or after 20 weeks. It should not be taken by nursing mothers due to the potential for infant adverse reactions.

Conditional Use The medicine is used with caution and requires monitoring in patients with pre-existing conditions like hypertension, compromised cardiac function, or hepatic disease. Dehydration or hypovolemia must be corrected prior to administration.

Prohibited Combinations and Restrictions

Co-administration of Potarlon with Aspirin or other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including cyclooxygenase-2 (COX-2) selective inhibitors, is strictly prohibited due to an increased risk of serious gastrointestinal events, such as bleeding and ulceration. The medicine is also formally contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Concomitant ingestion of alcohol increases the documented risk of serious gastrointestinal adverse events.

Documented Interaction Patterns

Potarlon enhances the effect of oral anticoagulants by displacing them from protein binding sites, necessitating frequent monitoring of prothrombin time. A heightened risk of gastrointestinal bleeding is documented when Potarlon is combined with SSRIs, corticosteroids, or other anti-platelet agents.

Pharmacokinetic interactions are documented with other specific medicines:

• Lithium and Methotrexate: Co-administration may reduce the renal clearance and elimination of these medicines, leading to potentially elevated plasma levels.
• ACE Inhibitors, ARBs, and Diuretics: Potarlon may decrease the antihypertensive or diuretic effects, and the combination increases the risk of renal impairment.
• Magnesium Hydroxide Antacids: Concomitant ingestion significantly increases the rate and extent of Potarlon's absorption.

Timing Rule: Potarlon should not be taken for 8–12 days following Mifepristone administration, as NSAIDs can reduce the effect of mifepristone.

Molecular Action on the Cyclooxygenase (COX) Enzymes

Potarlon (Mefenamic Acid) exerts its primary action by acting as a non-selective, competitive inhibitor of both the COX-1 and COX-2 enzymes. By interfering with these molecular targets, the drug directly prevents the conversion of arachidonic acid into various prostaglandins and thromboxanes. This essential molecular blockade initiates the subsequent physiological changes observed throughout the body.

---

Modulating Nociceptive Signal Transmission and Inflammatory Response

The reduction in prostaglandin synthesis modifies two critical physiological domains. Peripherally, the lowered prostaglandin concentration desensitizes the nociceptors (sensory nerve endings), which reduces the magnitude of the afferent pain signal transmitted to the CNS. Concurrently, the inhibition limits the release of pro-inflammatory prostaglandins at injury sites, thereby limiting localized vasodilation and subsequent fluid extravasation into tissues.

---

Central Regulation of Body Temperature Set Point

The drug’s mechanism also includes a central action within the hypothalamus, the brain’s thermoregulatory center. By inhibiting COX activity here, Potarlon prevents the pathological, PGE2-mediated elevation of the body’s temperature set point. This physiological reset initiates biological mechanisms that dissipate excess heat, enabling biological processes that lower core body temperature.

Administration Scope

Potarlon (Mefenamic Acid) is administered exclusively via the oral route as a capsule (250 mg) or tablet (500 mg). The medicine is designated for short-term use only, with administration typically not exceeding 7 days for acute pain or 2 to 3 days for primary dysmenorrhea.

Dosing Regimens and Frequency

The standard adult regimen begins with a single initial dose of 500 mg taken at the onset of symptoms. This is followed by a lower maintenance dose taken multiple times per day on an as-needed basis.

• US Regimen: The maintenance dose is 250 mg every 6 hours.
• EU Regimen: Regimens commonly specify 500 mg three times daily, illustrating that specific frequency patterns may vary by region.

Contextual Use and Special Populations

To ensure proper administration, Potarlon should be taken with food or milk. The principle is to use the lowest effective dose for the shortest possible duration, a principle applied to older adults. Dosing rules for pediatric patients differ, with the medicine generally not recommended for pain relief in children under 14 years of age. If a dose is missed, the general practice is to skip the missed dose if the next scheduled time is near and never double the dose. This overall protocol defines use as a temporary, as-needed course.

Evidence for Menstrual-Related Conditions: Dysmenorrhea and Menorrhagia

Potarlon was studied in research contexts involving episodic manifestations like primary dysmenorrhea and heavy menstrual bleeding. Research exploring outcomes related to physical discomfort has primarily utilized Randomized Controlled Trials (RCTs) and Systematic Reviews, including studies on women of reproductive age. Research examined how symptoms evolved, with outcomes focusing on patient-reported discomfort and the objective volume of menstrual blood loss (measured in milliliters). The findings describe patterns observed in the studies, but variability in the reported outcomes was observed in some studies, and research does not determine whether an individual will respond similarly.

---

Evidence for General Acute Pain

Research examining patient-reported pain includes Controlled Clinical Trials and Meta-Analyses applied in studies involving symptoms linked to acute episodes, such as dental or post-operative discomfort. These trials focused on outcomes related to physical discomfort in adults and adolescents (ge 14 years of age). Studies monitored patient functional status and symptom intensity over defined time intervals. The evidence is derived from short-term models, with observation periods typically lasting less than one week.

---

Long-Term Evidence and Follow-up Duration

Understanding the duration of observation is key to contextualizing the evidence. For general acute pain, the research highlights that data are structurally limited to very short time intervals. For heavy menstrual bleeding, follow-up durations were typically longer, with some extension studies monitoring outcomes for up to 12 to 15 months. Overall, research describes short-term changes during episodic use, but long-term outcomes are not fully established.

---

Evidence in Specific Patient Populations

The existing research has included adolescent females (ge 14 years of age) in trials related to primary dysmenorrhea and acute pain. The data show patterns observed in these specific groups. For older adults or patients with comorbid conditions, data for these groups remain insufficient, meaning there is limited information to draw conclusions about how these populations might respond.

---

Understanding Evidence Gaps and Areas of Uncertainty

This final section describes the major limitations and research gaps documented in scientific assessments. A major gap is the limited information for long-term outcomes across all indications. Evidence quality varies across studies, and comparative evidence is lacking for many potential uses. The existing evidence base provides context but not individual predictions.

Key Studies & References

1. Mefenamic Acid - LiverTox (National Library of Medicine Monograph)

Common questions about Potarlon (FAQ)

---

Q: How quickly should I expect to see an effect from Potarlon?

Potarlon is generally described in official information as having a prompt action to address acute symptoms. The elimination half-life of its active ingredient, Mefenamic Acid, is approximately two hours, which gives an indication of how long the medicine stays active in the body. The duration of relief observed can vary between individuals, as the medicine is intended for short-term, as-needed use.

---

Q: Why do some people refer to Potarlon as a 'daily medication'?

Official regulatory documents clearly designate the medicine for short-term use only and not for continuous daily use. Treatment periods are typically restricted to no more than one week for acute conditions. The medicine is intended to be taken on an as-needed basis when symptoms occur, not as a maintenance drug.

---

Q: Does Potarlon cause drowsiness or affect alertness?

The official safety profile includes reactions that affect the nervous system, such as dizziness and headache. Official labeling indicates that caution is necessary regarding these effects, particularly before operating complex machinery.

---

Q: How does Potarlon differ from [Similar Drug Name]?

Potarlon's active ingredient is Mefenamic Acid, which is classified as part of the fenamate group of Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This classification is a structural categorization that differentiates it from other common NSAIDs like ibuprofen or naproxen.

---

Q: Is Potarlon a controlled substance?

Potarlon is classified by regulatory authorities as a prescription-only (Rx-only) medicine, meaning it requires a prescription from a healthcare professional for use. It is not currently listed as a controlled substance in major regulatory schedules.

---

Q: Are there specific symptoms that mean I should contact a healthcare provider about Potarlon?

Official labeling identifies certain rare but serious adverse reactions that are described as requiring prompt medical attention. Symptoms described include signs of cardiovascular events, like chest pain or shortness of breath, or signs of severe gastrointestinal issues, such as unusual bleeding or ulceration.

---

Q: How long does Potarlon stay in my system?

The half-life of the active ingredient is approximately two hours, which describes the time it takes for half of the drug to be eliminated from the body. Official pharmacokinetic information indicates that the medicine is eliminated through both the kidneys (urine) and the liver (faeces).

---

Q: Does using Potarlon affect my ability to drive?

Adverse effects affecting the nervous system, such as dizziness, are documented in the official safety profile. Regulatory information advises patients that operating complex machinery should be avoided if adverse effects like dizziness occur.

---

Q: Does Potarlon affect blood pressure?

Official regulatory documents advise caution when the medicine is used in patients with pre-existing conditions, including hypertension (high blood pressure) or compromised heart function. This is because regulatory guidance requires caution for this population when using NSAIDs.

---

Q: Are there generic versions of Potarlon available?

The active ingredient in Potarlon is Mefenamic Acid. Regulatory bodies, such as the FDA, have approved generic versions of this drug.

---

Q: What is the recommended storage temperature for Potarlon?

Official storage requirements mandate that the drug be kept at 20 to 25 C (68 to 77 F). This temperature range is defined in the United States as USP Controlled Room Temperature. Official labeling states the original container is required to be kept tightly closed to protect the contents from moisture.

---

Q: Why do official documents emphasize taking Potarlon consistently?

Official guidance emphasizes using the lowest effective dose for the shortest possible duration. The medicine is designed to be taken as needed for acute symptoms, such as pain or fever, rather than being taken consistently every day for long periods.

---

Q: Does Potarlon interact with herbal remedies like St. John's Wort?

The official labeling provides comprehensive interaction information for many prescription medications. However, the safety of combining Potarlon with specific herbal remedies and supplements may not be established in official documentation. Regulatory documents suggest that general caution is appropriate regarding concomitant use of substances that could increase the risk of adverse effects.

---

Q: How is Potarlon eliminated from the body?

Official pharmacokinetic information describes how the drug is processed and removed from the body. The medicine is primarily eliminated through two major pathways: via the kidneys (urine) and via the liver (faeces).

---

Q: If I stop taking Potarlon, what happens?

Since the medicine is intended for short-term, as-needed relief, its therapeutic effects will gradually subside after the last dose. This occurs as the medicine is naturally processed and eliminated from the body over time.

---

Q: What does 'contraindicated' mean in relation to Potarlon?

When a medicine is officially described as contraindicated, it means that specific patient conditions or circumstances exist where the drug must not be used. This is based on regulatory assessment that, in these specific cases, the risks of using the medicine are considered to be greater than any potential benefit.

---

Q: What are the potential effects of taking too much Potarlon?

Official labeling documents list the potential effects of taking more than the prescribed amount. Reported serious effects can include seizures and various other symptoms affecting the central nervous system. Official labeling states that immediate professional medical attention is required if an accidental overdose is suspected.

---

Q: What is the shelf life of Potarlon?

Regulatory documents define the required stability and shelf life of the product. The official expiration date for the unopened container is determined by the manufacturer and is printed directly on the product's packaging. Official documents describe the medicine as not recommended for use past this printed date.

---

Q: Why do I need a prescription for Potarlon?

Regulatory authorities classify the medicine as prescription-only (Rx-only) due to its documented safety profile and the potential for serious adverse effects. This classification indicates that a healthcare professional must assess the individual’s medical history to determine if the benefits of the medicine are anticipated to outweigh the known risks.

---

Q: Are there any specific tests required before starting Potarlon?

Regulatory guidance specifies that correction or monitoring of pre-existing conditions, such as dehydration or compromised renal function, is required prior to and during administration. This is necessary because the medicine belongs to a class that can affect kidney function in susceptible individuals.

Regulatory documents define highly specific requirements for storing and disposing of medicines to ensure their stability and safety.

Storage Requirements

Classification	Requirement
Storage Constraints	The drug must be stored only in its original container and must not be placed in external containers, such as pill boxes or organizers, to protect the contents from moisture.
In-Use Stability	After the original bottle is opened, the contents must be used within 60 days.
Handling	The container must be immediately closed tightly after each use, removing only one capsule at the time of administration.

Disposal Instructions

Classification	Requirement
Best Option	Use a recognized drug take-back location or a prepaid mail-back envelope for disposal.
Alternative Disposal	If a take-back option is unavailable and the medicine is not on the official FDA Flush List, mix the medicine with an unappealing substance (such as used coffee grounds or dirt), seal it in a bag or container, and discard it in the household trash.
Container Preparation	All personal information on the empty packaging must be scratched out before disposal to maintain privacy.